HDAC9 and plasma cell myeloma: Instead, the pan-HDAC inhibitor, panobinostat, which has shown promise treating patients with multiple myeloma [68], has also demonstrated targeted killing of primary JMML HSPCs, interestingly showing greater efficacy than 5-azacytidine in vitro [69].